1 |
Blaner WS, O'Byrne SM, Wongsiriroj N, et al. Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage. Biochim Biophys Acta 2009; 1791: 467-73.
|
2 |
Testerink N, Ajat M, Houweling M, et al. Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of HSCs during activation. PLoS One 2012; 7: e34945.
|
3 |
Herńndez-Gea V, Friedman SL. Autophagy fuels tissue fibrogenesis. Autophagy 2012; 8: 849-50.
|
4 |
Tang Y, Chen A. Curcumin protects HSCs against leptin- induced activation in vitro by accumulating intracellular lipids. Endocrinology 2010; 151: 4168-77.
|
5 |
Tsukamoto H. Fat paradox in liver disease. Keio J Med 2005; 54: 190-2.
|
6 |
Chen A, Tang Y, Davis V, et al. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet induced nonalcoholic fatty liver disease. Hepatology 2013; 57: 2202-12.
|
7 |
Zhang W, Wu R, Zhang F, et al. Thiazolidinediones improve hepatic fibrosis by activating the adenosine monophosphate- activated protein kinase (ampk) signaling pathway in rats with non-alcoholic steatohepatitis. Clin Exp Pharmacol Physiol 2012; 39: 1026-33.
|
8 |
Gäbele EF, Dorn C, Patsenker E, et al. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol Clin Exp Res 2011; 35: 1361-7.
|
9 |
Nakano S, Nagasawa T, Ijiro T, et al. Bezafibrate prevents HSCs activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol Res 2008; 38: 1026-39.
|
1 |
0.Galli A, Crabb D, Price D, et al. Peroxisome proliferator- activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human HSCs. Hepatology 2000; 31: 101-8.
|
|
1.Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 360: 1410-8.
|
|
2.Kainuma M, Fujimoto M, Sekiya N, et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006; 41: 971-80.
|
|
3.Ferré N, Martínez-Clemente M, López-Parra M, et al. Increased susceptibility to exacerbated liver injury in hyper- cholesterolemic ApoE-deficient mice: Potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009; 296: G553-62.
|
|
4.Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665-74.
|
|
5.Bie J, Zhao B, Song J, et al. Improved insulin sensitivity in high fat- and high cholesterol-fed Ldlr-/- mice with macrophage- specific transgenic expression of cholesteryl ester hydrolase: Role of macrophage inflammation and infiltration into adipose tissue. J Biol Chem 2010; 285: 13630-7.
|
|
6.Vincent M, Sayre NL, Graham MJ, et al. Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease. PLoS One 2010; 5: e12941.
|
|
7.Bieghs V, Hendrikx T, van Gorp PJ, et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology 2013; 144: 167-78.
|
|
8.Tokunaga T, Ikegami T, Yoshizumi T, et al. Beneficial effects of fluvastatin on liver microcirculation and regeneration after massive hepatectomy in rats. Dig Dis Sci 2008; 53: 2989-94.
|
|
9.Aprigliano I, Dudas J, Ramadori G, et al. Atorvastatin induces apoptosis by a caspase-9-dependent pathway: An in vitro study on activated rat HSCs. Liver Int 2008; 28: 546-57.
|
2 |
0.Yang Q, Liu HY, Zhang YW, et al. Anandamide induces cell death through lipid rafts in HSCs. J Gastroenterol Hepatol 2010; 25: 991-1001.
|
|
1.Li T, Chiang JY. A novel role of transforming growth factor beta1 in transcriptional repression of human cholesterol 7 alpha-hydroxylase gene. Gastroenterology 2007; 133: 1660-9.
|
|
2.Lee YS, Jeong WI. Retinoic acids and HSCs in liver disease. J Gastroenterol Hepatol 2012; 27: S75-9.
|
|
3.Senoo H, Yoshikawa K, Morii M, et al. HSCs (vitamin A-storing cell) and its relative—past, present and future. Cell Biol Int 2010; 34: 1247-72.
|
|
4.Mukhopadhyay B, Liu J, Osei-Hyiaman D, et al. Transcri- ptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor- gamma. J Biol Chem 2010; 285: 19002-11.
|
|
5.He H, Mennone A, Boyer JL, et al. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011; 53: 548-57.
|
|
6.Lee TF, Mak KM, Rackovsky O, et al. Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). J Cell Physiol 2010; 223: 648-57.
|
|
7.Son G, Hines IN, Lindquist J, et al. Inhibition of phosphatidy- linositol 3-kinase signaling in HSCs blocks the progression of hepatic fibrosis. Hepatology 2009; 50: 1512-23.
|